The Artisan Mid Cap Fund reported strong performance in the second quarter, with its Investor Class shares returning 17.86%, outperforming the Russell Midcap Growth Index’s 14.55% gain. Global equities rebounded sharply during the period, recovering from earlier declines as economic resilience, solid corporate earnings, and continued investment in artificial intelligence bolstered market sentiment. Healthcare emerged as the largest contributor to fund performance, with biotech holdings delivering significant gains alongside strong consumer discretionary positions.
Twist Bioscience Corporation, a synthetic DNA manufacturer, was highlighted as a notable contributor to the fund’s results. The company’s stock closed at $124.72 per share on September 04, 2026, and had appreciated 375.12% over the preceding 52 weeks, though it declined 0.13% during the most recent month. The company commands a market capitalization of $8.21 billion and has traded within a 52-week range of $23.30 to $155.44.
According to the fund’s commentary, Twist Bioscience leverages proprietary silicon-based DNA writing technology with applications spanning drug discovery, diagnostics, agriculture, and industrial materials. The company’s recent financial results surpassed expectations, bolstered by strong performance in its DNA synthesis and protein solutions segment alongside growth acceleration in next-generation sequencing offerings. The fund noted that Twist Bioscience continues benefiting from expanding demand by large pharmaceutical firms and artificial intelligence-focused customers for DNA synthesis and data generation services.
The fund’s managers indicated that computational drug discovery approaches are gaining broader industry adoption, positioning the company for potential incremental growth. However, the fund reduced its Twist Bioscience position during the quarter following the stock’s substantial appreciation. Hedge fund interest in the company has increased, with 42 hedge fund portfolios holding the stock at the end of the second quarter, up from 30 portfolios in the previous quarter.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI